What question did this study set out to answer?

The aim is to explore how inhibiting KIF23 affects cell proliferation and chemoresistance in cervical cancer.

April 8, 2026Open Access

Targeting KIF23 inhibits cell proliferation and primary chemoresistance in cervical cancer by inactivating the MYH9/MCM2/PCNA pathway

YZYing ZhuShanghai Jiao Tong University QWQian WangWannan Medical College YZYuan ZhangThird Affiliated Hospital of Southern Medical University

Key Points

The aim is to explore how inhibiting KIF23 affects cell proliferation and chemoresistance in cervical cancer.
Monitored KIF23 expression in response to varying concentrations of cisplatin.
Analyzed the interaction between KIF23, MYH9, MCM2, and PCNA.
Studied the effects of targeting this pathway on cervical cancer cell responses to treatment.
KIF23 expression increased with higher cisplatin concentration and prolonged exposure.
Inhibition of KIF23 interfered with MYH9 stability and its role in nuclear transport.
Targeting the KIF23/MYH9/MCM2/PCNA pathway enhanced sensitivity of cervical cancer cells to cisplatin.

Abstract

Cisplatin treatment induces KIF23 expression in a concentration- and time-dependent manner. KIF23 recruits USP7, which removes the K48-linked ubiquitin chain of MYH9, thereby stabilising MYH9 and facilitating its nuclear transport. MYH9 recruits USP15, thereby stabilising MCM2, which, in turn, regulates the G1/S phase transition by binding to PCNA. Targeting the KIF23/MYH9/MCM2/PCNA axis sensitises cervical cancer cells to cisplatin.

AIに質問

Bookmark

View Full Paper

Cite This Study

Zhu et al. (Wed,) studied this question.

synapsesocial.com/papers/69d5f00974eaea4b11a79922 https://doi.org/https://doi.org/10.1002/ctm2.70652

AIに質問

Bookmark

View Full Paper